Recent headlines swirling around the swine flu have centered the focus of both the public and investors on vaccines and the vaccine industry. The vaccine marketplace is expected to show big gains through 2012 as it emerges as one of the most lucrative sectors of the global pharmaceutical industry. This bodes well for innovative companies such as TapImmune Inc. (OTCBB: TPIV).

TapImmune is a biotechnology company specializing in the development of cell-based vaccines and immunotherapeutics in the areas of oncology and infectious disease. The company’s vaccine technology is based on modulating the activity of the antigen processing machinery to increase effective presentation of antigens to the immune system. Transporters associated with antigen processing (TAP) play a major role in the antigen processing pathway.

One of the most lucrative areas for vaccine makers is vaccines which may treat various forms of cancer. The